Altmetric
Clinical, microbiological and metabolic features of patients with Crohn’s disease and intestinal failure
File | Description | Size | Format | |
---|---|---|---|---|
Bouri-S-2024-MD(Res)-Thesis.pdf | Thesis | 3 MB | Adobe PDF | View/Open |
Title: | Clinical, microbiological and metabolic features of patients with Crohn’s disease and intestinal failure |
Authors: | Bouri, Sonia |
Item Type: | Thesis or dissertation |
Abstract: | The pathogenesis of inflammatory bowel disease (IBD) involves the interaction between an individual’s genes, gut microbiota and environmental factors. The Crohn’s disease (CD) microbiome is characterised by a reduction in Firmicutes and an increase in Proteobacteria. The CD metabonome consistently shows a reduction in secondary bile acids (SBAs) and an increase in stool and serum primary bile acids (PBAs). Very few studies have examined the multiomic profile in patients with Crohn’s disease-intestinal failure (CD-IF). I present two retrospective case-control studies and one prospective multiomics study. I identified the following risk factors for the development of IF in patients with CD: female gender, ileocolonic involvement, penetrating disease and non-exposure to biologic medications. Patients with CD-IF are twice as likely to be in remission compared to patients with CD (without IF) and the strongest factor associated with active disease, was the presence of a surgical anastomosis to colon in continuity compared to those with an end enterostomy. For the multiomics study, stool, serum and urine samples from CD-IF patients were analysed. 16s rRNA sequencing demonstrated an expansion of aerotolerant and facultative anaerobic microorganisms, with a decrease in obligate anaerobes; the CD-IF gut luminal environment has a higher oxygen content. Metabonomic profiling showed a higher serum and faecal cholic acid and chenodeoxycholic acid in active disease compared to remission; this is in keeping with the theory that loss of bowel length leads to loss of farnesoid X receptor (FXR) and Fibroblast growth factor 19 (FGF19) and an increase in hepatic synthesis of PBAs. Expectedly, an almost absence of serum SBAs was observed in CD-IF. Multiomics changes seen with active disease could be a cause or a consequence of disease activity, or secondary to the anatomic changes or changes in diet and parenteral nutrition. |
Content Version: | Open Access |
Issue Date: | Apr-2023 |
Date Awarded: | May-2024 |
URI: | http://hdl.handle.net/10044/1/112008 |
DOI: | https://doi.org/10.25560/112008 |
Copyright Statement: | Creative Commons Attribution NonCommercial Licence |
Supervisor: | Hart, Ailsa |
Sponsor/Funder: | St Mark's Hospital Foundation |
Department: | Department of Metabolism, Digestion and Reproduction |
Publisher: | Imperial College London |
Qualification Level: | Doctoral |
Qualification Name: | Doctor of Medicine (Research) MD (Res) |
Appears in Collections: | Department of Metabolism, Digestion and Reproduction PhD Theses |
This item is licensed under a Creative Commons License